Collectively, these results suggest that tumor-derived SAA1 may act via TLR4 receptor to induce the activation of p38 and JNK signaling to disrupt cell–cell junctions of lymphatic vessels, promoting lymphatic invasion. The gene discussed is SAA1; the disease is neoplasm.